Anatolia Tani ve Biyoteknoloji Urunleri Arastirma Gelistirme Sanayi ve Ticaret AS
BBIST:ANGEN6.47
TRY
-0.39
(-5.69%)
Anatolia Tani ve Biyoteknoloji Urunleri Arastirma Gelistirme Sanayi ve Ticaret AS
BIST:ANGEN
(Istanbul Exchange)
Recent
price
6.47
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
TRY
•
in mil. unless spec.Working Capital
TRY
•
in mil. unless spec.Growth Rates
TRY
•
in mil. unless spec.Quarterly Revenue
TRY
•
in mil. unless spec.Quarterly Earnings Per Share
TRY
•
in mil. unless spec.Quarterly Dividends Per Share
TRY
•
in mil. unless spec.- Similar Companies
- Business
- Anatolia Tani ve Biyoteknoloji Urunleri Arastirma Gelistirme Sanayi ve Ticaret AS, commercially known as Anatolia Geneworks, is a Turkey-based biotechnology company that designs, develops, manufactures, and commercializes in vitro molecular diagnostic kits and automated laboratory equipment. Founded in 2010 and headquartered in Istanbul, Turkey, the company operates in the molecular diagnostics, life sciences, and healthcare sectors. Its core product portfolio includes Bosphore Real-Time PCR kits for the detection and quantification of infectious diseases, including viral hepatitis, respiratory viruses, gastrointestinal pathogens, sexually transmitted infections, and meningitis; Bosphore human genetics, oncology, and pharmacogenomics mutation detection assays; Magrev magnetic bead-based and column-based nucleic acid isolation and extraction kits; Montania Real-Time PCR thermal cyclers; Magrev automated nucleic acid extraction workstations; automated liquid handling and robotic PCR setup systems; and specialized molecular biology reagents, enzymes, and diagnostic consumables. The company distributes its products internationally to hospitals, clinical reference laboratories, blood banks, public health institutions, and research centers across Europe, the Middle East, Asia, Africa, and the Americas. In recent operations, Anatolia Geneworks has accelerated its global expansion through operational subsidiaries in Europe, including Italy and the Netherlands, while transitioning its product catalog to align with European Union In Vitro Diagnostic Medical Devices Regulation standards. The company has also expanded its research and development pipeline into high-throughput syndromic multiplex panels and oncology testing, broadened strategic international distribution partnerships, and scaled manufacturing infrastructure across its certified production facilities.